Figure 3. Expression differences of PIEZO2 in breast cancer patients based on different clinicopathological features, including age (A), nodal status (B), ER status (C), PR status (D), HER2 status (E), NPI score (F), SBR grade (G), basal-like status (H) and triple-negative status (I).